197894-77-2

Upstream product

• 56961-25-2 4-amino-3,5-dichlorobenzoic acid 
• 197895-08-2 (R)-3,9-diamino-1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one 
• 126149-54-0 (RS)-3-amino-5-phenyl-3,4,6,7,-tetrahydropyrrolo<3,2,1-jk><1,4>benzodiazepin-4(3H)-one 
• 126252-50-4 (3R)-3-amino-5-phenyl-3,4,6,7-tetrahydropyrrolo<3,2,1-jk><1,4>benzodiazepin-4(3H)-one 
• 27158-79-8 1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one 
• 197895-07-1 (R)-3-amino-9-nitro-1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one 
• 126167-36-0 1-phenyl-6,7-dihydro[1,4]diazepino[6,7,1-hi]indole-3,4-dione 3-oxime 

Relevant academic research and scientific papers

Pharmaceutical composition for preventing or treating a disease associated with an excess of IL-12-production

This invention relates to the use of a PDE4 inhibitor or a pharmacologically acceptable salt thereof for manufacturing a medicament for preventing or treating a disease associated with an excess in IL-12 production.

Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles: Discovery of potent, selective phosphodiesterase type 4 inhibitors

The synthesis, structure-activity relationships, and biological properties of a novel series of potent and selective phosphodiesterase type 4 (PDE4) inhibitors are described. These new aminodiazepinoindoles displayed in vitro PDE4 activity with submicromo

Diazepinoindoles as phosphodiesterase 4 inhibitors

Diazepinoindoles of formula (I), STR1 wherein A is mono- to trisubstituted aryl or heteroaryl, and B is an --OR1 or --NR2 R3 group where R1, R2 and R3 are particularly hydrogen, and racemic